Aprogen Biologics Inc.
Korea ExchangeTotal Valuation
Aprogen Biologics Inc. carries a market capitalization of 27.34B, placing it among publicly traded companies globally. Its enterprise value stands at 304.20B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 27.34B |
| Enterprise Value | 304.20B |
Share Statistics
Aprogen Biologics Inc. currently has 13.18M shares outstanding.
| Shares Outstanding | 13.18M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.74, and the price-to-book ratio stands at -0.18.
| PE Ratio | N/A |
| PS Ratio | 0.74 |
| PB Ratio | -0.18 |
| P/TBV Ratio | 0.22 |
| P/FCF Ratio | -1.90 |
| P/OCF Ratio | -1.60 |
Enterprise Valuation
| EV / Sales | 3.90 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Aprogen Biologics Inc. maintains a current ratio of 0.67, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 83.25, indicating elevated leverage, while an interest coverage ratio of -4.41 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.67 |
| Quick Ratio | 0.22 |
| Debt / Equity | 83.25 |
| Debt / EBITDA | -3.90 |
| Interest Coverage | -4.41 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -21.61 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.92 |
Taxes
| Income Tax | -1.08B |
| Effective Tax Rate | N/A |
Stock Price Statistics
Aprogen Biologics Inc.'s stock has declined approximately -79.02992% over the past 52 weeks. The 50-day moving average sits at 3,035.03, while the 200-day moving average is 6,081.32.
| Beta (5Y) | N/A |
| 52-Week Price Change | -79.02992% |
| 50-Day Moving Average | 3,035.03 |
| 200-Day Moving Average | 6,081.32 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Aprogen Biologics Inc. generated 78.00B in revenue and converted that into -131.21B in net income, yielding earnings per share of -9,900.29. EBITDA reached -58.25B, while operating income came in at -58.25B.
| Revenue | 78.00B |
| Gross Profit | -24.32B |
| Operating Income | -58.25B |
| Pretax Income | -130.89B |
| Net Income | -131.21B |
| EBITDA | -58.25B |
| EBIT | -58.25B |
| Earnings Per Share (EPS) | -9,900.29 |
Balance Sheet
Aprogen Biologics Inc. holds 50.10B in cash and equivalents against 227.15B in total debt, resulting in a net debt position of 186.03B. Total book value stands at -314.65B, with working capital of -74.70B providing operational flexibility.
| Cash & Cash Equivalents | 50.10B |
| Total Debt | 227.15B |
| Net Debt | 186.03B |
| Equity (Book Value) | -314.65B |
| Book Value Per Share | -23,997.07 |
| Working Capital | -74.70B |
Cash Flow
Aprogen Biologics Inc. produced -36.25B in operating cash flow over the past twelve months. After subtracting -5.71B in capital expenditures, free cash flow totaled -41.96B - equivalent to -3,200.18 per share.
| Operating Cash Flow | -36.25B |
| Capital Expenditures | -5.71B |
| Free Cash Flow | -41.96B |
| FCF Per Share | -3,200.18 |
Margins
Aprogen Biologics Inc. operates with a gross margin of -31.18, reflecting its pricing power and cost economics. The operating margin of -74.68 and net profit margin of -168.22 provide insight into operational efficiency.
| Gross Margin | -31.18 |
| Operating Margin | -74.68 |
| Pretax Margin | -167.81 |
| Profit Margin | -168.22 |
| EBITDA Margin | -74.68 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -103.05 |
| FCF Yield | -52.68 |
Stock Splits
Aprogen Biologics Inc.'s most recent stock split took place on April 13, 2026 with a 10000:667 split ratio.
| Last Split Date | 4/13/2026 |
| Split Ratio | 10000:667 |
Scores
Aprogen Biologics Inc. posts an Altman Z-Score of -1.25, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.25 |